Title : Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.

Pub. Date : 2022 Jan 15

PMID : 34716196






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 EXPERIMENTAL DESIGN: From this 2-part phase 1, multicenter study, pexidartinib, a small molecule tyrosine kinase inhibitor that targets CSF1R, KIT, and FMS-like tyrosine kinase 3 (FLT3), was evaluated in 6 adult patient cohorts (part 2, extension) with advanced solid tumors associated with dysregulated CSF1R. pexidartinib fms related receptor tyrosine kinase 3 Homo sapiens
2 EXPERIMENTAL DESIGN: From this 2-part phase 1, multicenter study, pexidartinib, a small molecule tyrosine kinase inhibitor that targets CSF1R, KIT, and FMS-like tyrosine kinase 3 (FLT3), was evaluated in 6 adult patient cohorts (part 2, extension) with advanced solid tumors associated with dysregulated CSF1R. pexidartinib fms related receptor tyrosine kinase 3 Homo sapiens